Healius Needs Longer in Recovery Room -- Market Talk

Dow Jones

Aug 25, 2025

0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that "sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing." Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

August 24, 2025 21:01 ET (01:01 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562229309"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562229309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562229309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562229309","market":"sh","top_or_hot":-1,"title":"Healius Needs Longer in Recovery Room -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius Needs Longer in Recovery Room -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius Needs Longer in Recovery Room -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-25 09:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7509","symbol_name":"中概股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562229309","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562229309","pubTimestamp":1756083660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7509":"中概股","BK7124":"保健护理服务","HLS.AU":"HEALIUS LTD","BK7501":"新冠治疗股"},"translate_title":"Healius需要在恢复室呆更长时间——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 24, 2025 21:01 ET (01:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}